Jay Flatley is the former CEO and director of Illumina. He currently serves as executive chairman.
During his time as CEO, Flatley directed the company’s expansion from microarrays to next-generation sequencing via its 2006 acquisition of Solexa, and more recently from research to clinical and applied markets.
Prior to Illumina, Flatley was co-founder, president, CEO, and a director for Molecular Dynamics, a life sciences company concentrated on genetic discovery and analysis. He remained there until the company’s sale to Amersham Pharmacia Biotech in 1998.
Previously, he served as vice president of engineering and vice president of strategic planning for Plexus Computers. He was also a director for Coherent, a photonics-based solutions provider for commercial and scientific markets.
During Flatley’s tenure at Illumina, the company was recognized multiple times on the Deloitte & Touche “Fast 50” and “Fast 500” lists, and Forbes’ list of the “25 Fastest-Growing Tech Companies” in 2007, 2009 and 2010. It was also named to Fortune’s “100 Fastest-Growing Companies” list in 2010 and 2011. Additionally, MIT Technology Review recognized it as the “World’s Smartest Company” in 2014.
Flatley received his bachelor of arts in economics from Claremont McKenna College. He also received both his bachelor of science and master of science in industrial engineering at Stanford University.
Within the last three months, Jay T. Flatley has sold $1,693,760.00 in Illumina stock. Most recently, Jay T. Flatley sold 4,000 shares of the business's stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $423.44, for a transaction totalling $1,693,760.00.